1.0g

Name: Ceftazidime for Injection with GMP 0.25g/0.5g/1.0g
Brand: REYOUNG PHARMACEUTICAL CO., LTD.
SKU: 937825215

Shandong, ChinaREYOUNG PHARMACEUTICAL CO., LTD.

US$47.30-55.48

7,500 Pieces

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For external use

Model NO.

0.25g/0.5g/1.0g

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Oral Liquid

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

H20013187

Indate

3years

Sterile

Color

White

Standard

Bp/Cp

Transport Package

50vials/Tray/Box, 20boxes/Carton

Specification

0.25g/0.5g/1.0g

Trademark

Reyoung

Origin

China

HS Code

3003101900

Production Capacity

20000000vials/Year

Company profile

REYOUNG PHARMACEUTICAL CO., LTD.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 1997-01-01 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryReyoung Pharmaceutical Co., Ltd., established in 1966, is a leading pharmaceutical manufacturer based in Shandong, China. The company operates over 10 production lines, producing a variety of pharmaceutical products and exporting to South America, Africa, and Southeast Asia. It holds several certifications including ISO9001, ISO14001, and OHSAS18001. With a workforce of approximately 4950 employees, including 370 R&D engineers and 50 quality control staff, Reyoung Pharma demonstrates a strong emphasis on quality and innovation. The company has a significant annual production output and engages in international trade with countries like India and Bolivia.

Supplier typeReyoung Pharmaceutical Co., Ltd. is a combined manufacturing and distribution entity, operating as a limited company in Shandong, China.

CertificationsThe supplier holds ISO9001:2015, ISO14001:2015, and OHSAS18001:2007 certifications, indicating compliance with quality, environmental, and occupational health standards.

Financial creditReyoung Pharma has a registered capital of 78,560,000 RMB and owns assets worth over 1.5 billion USD, suggesting substantial financial stability.

R&D capabilityWith 370 R&D engineers, Reyoung Pharma shows a strong commitment to innovation in its pharmaceutical products.

Production capacityThe supplier operates above 10 production lines with an annual output exceeding US$100 million, demonstrating significant production capacity.

Client casesReyoung Pharma has engaged in trade transactions with companies like Sterile India Private Limited and Heredia Aracena Reny Evelin, illustrating international customer engagement.